Liu Li Ying, Wang Wei, Zhao Ling Yu, Guo Bo, Yang Juan, Zhao Xiao Ge, Song Tu Sheng, Huang Chen, Xu Ji Ru
Center Laboratory of Biomedical Research, Key Laboratory of Environment and Genes Related to Diseases of Chinese Ministry of Education, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi 710061, P.R. China.
Department of Orthopaedic Surgery, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710004, P.R. China.
Mol Med Rep. 2015 Apr;11(4):3033-8. doi: 10.3892/mmr.2014.3077. Epub 2014 Dec 11.
Polo‑like kinase 2 (PLK2) is a serine/threonine protein kinase, which has vital roles during mitosis and the centrosome cycle. In acute myeloblastic leukemia and hepatocarcinogenesis, PLK2 acts as a tumor suppressor; however, the function of PLK2 in gastric cancer remains to be elucidated. In the present study, PLK2 was overexpressed in gastric cancer tissues and three types of gastric cancer cells, SGC‑7901, MKN‑45 and BGC‑823. Transfection of SGC‑7901 gastric cancer cells with small interfering (si)RNA against PLK2 exerted no effect on the ratio of cells at different stages of the cell cycle compared with that of the untransfected and control siRNA‑transfected cells. In addition, silencing of PLK2 significantly enhanced the growth of SGC‑7901 cells through inhibiting apoptosis. Furthermore, apoptosis‑associated genes Bax and caspase 3 were found to be downregulated at the protein level. In conclusion, these results suggested that PLK2 may act as a tumor suppressor in gastric cancer, therefore indicating its therapeutic potential.
Polo样激酶2(PLK2)是一种丝氨酸/苏氨酸蛋白激酶,在有丝分裂和中心体循环过程中发挥着重要作用。在急性髓细胞白血病和肝癌发生过程中,PLK2作为一种肿瘤抑制因子发挥作用;然而,PLK2在胃癌中的功能仍有待阐明。在本研究中,PLK2在胃癌组织以及三种胃癌细胞SGC-7901、MKN-45和BGC-823中过表达。与未转染和对照小干扰(si)RNA转染的细胞相比,用针对PLK2的siRNA转染SGC-7901胃癌细胞对处于细胞周期不同阶段的细胞比例没有影响。此外,PLK2的沉默通过抑制凋亡显著增强了SGC-7901细胞的生长。此外,发现凋亡相关基因Bax和半胱天冬酶3在蛋白水平下调。总之,这些结果表明PLK2在胃癌中可能作为一种肿瘤抑制因子发挥作用,因此显示出其治疗潜力。